The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).
Ines Maria Vaz Duarte Luis
Research Funding - Eisai; Genentech; Myriad Genetics
Melissa E Hughes
No relevant relationships to disclose
Angel Cronin
No relevant relationships to disclose
Hope S. Rugo
No relevant relationships to disclose
Stephen B. Edge
No relevant relationships to disclose
Beverly Moy
No relevant relationships to disclose
Richard L. Theriault
No relevant relationships to disclose
Eric P. Winer
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Nancy U. Lin
Research Funding - Array BioPharma; Genentech; GlaxoSmithKline